Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Trump’s Funding Cuts Halt Rollout Of HIV Prevention Drug
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Opinion
Hosted on MSN23hOpinion
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...
Hosted on MSN6h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
Managed Healthcare Executive1h
FDA Accepts BLA Resubmission for Follicular Lymphoma Drug, Odronextamab
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
Healio2h
Q&A: How can implementation of long-acting injectables for HIV prevention be improved?
A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables ...